An international consensus group has recommended renaming PCOS to polyendocrine metabolic ovarian syndrome (PMOS). The new terminology is intended to better reflect the endocrine and metabolic ...

The FDA has approved Avlayah (tividenofusp alfa-eknm) to treat the neurological manifestations of Hunter syndrome in pediatric patients. In a phase 1/2 clinical trial, the treatment led to a 91% ...

Chad Wells, PhD, shares evidence-based strategies to improve MenACWY 2-dose series completion and address racial and socioeconomic disparities in vaccination. According to Chad Wells, PhD, ...

Higher social media use in childhood was associated with increasing inattentive ADHD symptoms over time, while other digital media types showed differen Video gaming and television or video viewing ...

Clinicians now have the first oral alternative to injectable therapy for gonorrhea, a shift Angela Hasler, APRN, CPNP-PC says could ease treatment barriers and improve public health outcomes.

The FDA approved Daybue Stix, a powder formulation of trofinetide, for Rett syndrome in patients 2 years or older. New formulation, same clinical expectations: The FDA approval of DAYBUE STIX provides ...

A phase 1b study of zelpultide alfa demonstrated a favorable safety profile and encouraging early reductions in BPD and ventilation duration, supporting advancement to a pivotal international Phase 2b ...

National CPS data from 2012-2023 show declines in confirmed child maltreatment, but disparities remained, particularly among Black and female children. Confirmed child maltreatment declined, but ...

FDA grants Breakthrough Device Designation to GeneDx genome and exome tests supporting diagnosis of life-threatening genetic disorders. The FDA has granted Breakthrough Device Designation to GeneDx’s ...

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data. Compared with ...

The Committee voted against a proposed recommendation that "state and local jurisdictions should require a prescription for the administration of a COVID-19 vaccination.

FDA approves updated COVID-19 vaccines for 2025-2026 but limits pediatric access, restricting use to older and high-risk groups. On August 27, the FDA authorized updated formulations of COVID-19 ...